STAT+: Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
CHICAGO — Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a mid-stage trial, results that support the company’s decision to use a slower dosing schedule to make the drug more tolerable in further testing. In the Phase 2 study, patients with obesity taking the […]
Food structure shown to play key role in which gut hormones are released
A new study from Imperial has shown that the physical structure of food influences the hormones released as part of digestion. These hormones include glucagon-like peptide-1 (GLP-1), GIP and PYY, as well as other post-meal responses like blood sugar, insulin and satiety hormones.
Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated – Expect Volatility
Post Content
“You’ll never go broke making people skinny”: Denmark’s economy skyrockets—all thanks to high demand for weight-loss drugs Ozempic and Wegovy
Making people skinny is fattening Denmark’s pockets. According to the BBC, Danish pharmaceutical firm Novo Nordisk is cashing in after the release of two extremely popular drugs: Wegovy and Ozempic. The anti-obesity and diabetic medications turned the pharmaceutical company into one of Europe’s most valuable companies. How much have WeGovy and Ozempic boosted profits? According […]
Novel Molecule May Rival GLP-1s for Diabetes and Obesity Treatment
The popularity of GLP-1-based drugs is testament to the importance of a drug that increases fat burning and lowers blood sugar. Now, a new drug—taken in the form of a tablet—offers the outcome of GLP-1-based drugs (which are administered via injection) but with a different mechanism of action. GLP-1 drugs affect hunger via signals between […]
STAT+: Pharmalittle: We’re reading about Novo ending Hims deal, FDA transparency, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause button to stop the world, such as it is, from spinning. So this means one thing: time […]
Corxel, Sciwind post GLP-1 data as China’s obesity push gathers pace
The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with Corxel Pharmaceuticals and Sciwind Biosciences among the companies to share data at the event.
Shiru invites brands to harness its AI platform to explore ‘natural’ GLP-1 activation: ‘The opportunity is immense’
Shiru, a startup deploying AI to aid in ingredient discovery, is inviting food companies to use its platform to explore ingredients that naturally stimulate production of GLP-1, a gut hormone associated with appetite regulation. The new GLP-1 Innovation Alliance, an industry consortium that invites “Fortune 500 CPG companies and emerging brands to collaborate as equals” […]
China’s GLP-1 Shows Similar Weight Loss to Wegovy
Overweight patients given an experimental weight loss drug being developed by China’s Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line… Reuters Health Information
STAT+: Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs
Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.” Earlier this year Novo launched a direct-to-consumer website that sells Wegovy at a lower price to patients who are paying on their own without insurance. […]